Compare · Healthcare
Cipla vs Sun Pharma: how their businesses differ
The same facts for both companies, in the same order, from each company's own page and filings. It is not a ranking.
How they differ
In FY26, Sun Pharma's revenue of ₹58,462 cr was about 2.1 times Cipla's ₹28,163 cr (Cityfort calculation: one divided by the other).
Cipla's largest segment is One India, 45.0% of revenue in FY26; Sun Pharma's largest segment is India, 33.8% of revenue in FY26.
India brought in 45.0% of Cipla's revenue in FY26.
Cipla's largest payer group is Customers in India, 45.0% of revenue (FY26); Sun Pharma's largest payer group is Buyers in India, 33.8% of revenue (FY26).
Each page lists the other among its competitors.
Each company in 5 points
Cipla
1 · What it sells
Cipla makes branded and generic medicines, including inhalers for breathing conditions, and its FY26 revenue from operations was ₹28,163 crore.
Sources and detail on the Cipla page2 · Who pays it
In FY26, customers in India paid 45.0% of Cipla's revenue, the US 24.4%, Africa 15.2% and the rest of the world 15.4%.
Sources and detail on the Cipla page3 · What it keeps from ₹100
Of every ₹100 that came in during FY26, Cipla kept ₹13.4 as profit, after a ₹276 crore one-off labour-code charge and including ₹882 crore of other income, while its EBITDA before the one-off charge was 20.9% of revenue (Cityfort calculation).
Sources and detail on the Cipla page4 · Where the operating profit comes from
Cipla has reported a single segment since FY26, so it does not disclose which business earns its FY26 EBITDA of ₹5,883 crore before the one-off charge (Cityfort calculation); India gave 45.0% of revenue.
Sources and detail on the Cipla page5 · The one thing to watch
North America sales fell from US$233 million in Q2 FY26 to US$172 million in Q2 FY27, and management said on 27 Oct 2026 it keeps its aim of a US$1 billion run rate towards the end of FY27.
Sources and detail on the Cipla page
Sun Pharma
1 · What it sells
Sun Pharma makes branded medicines for India, generic medicines for the US and other countries, and patented drugs such as Ilumya, and its FY26 revenue from operations was ₹58,462 crore.
Sources and detail on the Sun Pharma page2 · Who pays it
In FY26, buyers in India paid 33.8% of Sun Pharma's sales, buyers in the US 30.3%, emerging markets 20.1% and the rest of the world 15.8%.
Sources and detail on the Sun Pharma page3 · What it keeps from ₹100
Of every ₹100 that came in during FY26, Sun Pharma kept ₹19.0 as profit after ₹2.2 of one-off charges, and in Q2 FY27 a ₹1,269 crore one-off charge cut profit to ₹1,989 crore while profit before one-off items and tax rose 6.3% to ₹4,428 crore.
Sources and detail on the Sun Pharma page4 · Where the operating profit comes from
Sun Pharma does not report profit by region or product, so the source of its FY26 EBITDA of ₹16,424 crore is not disclosed; patented innovative medicines were 20.7% of its sales, excluding a milestone payment.
Sources and detail on the Sun Pharma page5 · The one thing to watch
Sun Pharma agreed on 27 Apr 2026 to buy Organon, a company with US$6.2 billion of 2025 revenue, for an enterprise value of US$11.75 billion, and management said on 30 Oct 2026 it expects completion in Q4 FY27.
Sources and detail on the Sun Pharma page
Where each ₹100 went
Each company's own receipt for its latest full financial year, with matching lines in the same order where both have them.
Cipla
Where ₹100 went · FY26
| Materials and goods bought | ₹32.9 |
|---|---|
| Employee costs | ₹18.5 |
| Other running costs | ₹25.4 |
| Depreciation and interest | ₹4.4 |
| One-off labour-code charge | ₹0.9 |
| Income tax | ₹4.7 |
| Kept as profit for shareholders | ₹13.4 |
| Total | ₹100 |
Cityfort calculation from the FY26 annual report: each line ÷ total money in (revenue of ₹28,163 crore plus ₹882 crore of other income) × 100. Profit is the shareholders' share: ₹9 crore more than money in minus the costs shown, because minority partners took ₹17 crore of losses and part-owned companies lost ₹8 crore.
Sun Pharma
Where ₹100 went · FY26
| Materials and goods bought | ₹19.1 |
|---|---|
| Employee costs | ₹18.9 |
| Other running costs (research, marketing, freight) | ₹29.4 |
| Depreciation, interest and small items | ₹5.5 |
| One-off charges | ₹2.2 |
| Income tax | ₹5.9 |
| Kept as profit for shareholders | ₹19.0 |
| Total | ₹100 |
Of every ₹100 that came in during FY26 (revenue of ₹58,462 crore plus ₹1,972 crore of other income), Sun Pharma kept ₹19.0 as profit for shareholders, after ₹2.2 of one-off charges.
Line items differ because each company groups its costs its own way in its filings. Only on Cipla's receipt: Other running costs; Depreciation and interest; One-off labour-code charge. Only on Sun Pharma's receipt: Other running costs (research, marketing, freight); Depreciation, interest and small items; One-off charges.
Revenue, net profit and free cash flow
Up to five financial years for each company, drawn on one shared scale per measure. Amounts in ₹ crore as each company reports them.
Revenue
Cipla
Sun Pharma
See the numbers
Net profit
Cipla
Sun Pharma
See the numbers
Free cash flow
Cipla
Sun Pharma
See the numbers
Sources: Cipla S34, S5, S4, S33, S32, S3, S26, S2, S15, S1, S16 · Sun Pharma S7, S6, S5, S1
Growth and net margin, FY22 to FY26
Worked out over the years both pages cover, so the two growth figures use the same span. Net margin is net profit as a share of revenue, as on each page.
Cipla
- Revenue, per year
- +6.7%
- Net profit, per year
- +11.4%
Sun Pharma
- Revenue, per year
- +10.9%
- Net profit, per year
- +36.8%
Cityfort calculation: compound growth per year from FY22 to FY26 (4 years), from each page's yearly numbers, as reported.
Net margin by year
Sources: Cipla S34, S5, S4, S33, S32, S3, S26, S2, S15, S1, S16 · Sun Pharma S7, S6, S5, S1
Latest quarter, against the same quarter a year earlier
Each page's latest quarter as reported; the change is a Cityfort calculation.
Cipla
Q2 FY27, the quarter to 30 Sep 2026, against Q2 FY26
| Measure | Q2 FY27 | Q2 FY26 | Change |
|---|---|---|---|
| Revenue | ₹7,404 cr | ₹7,589 cr | −2.4% |
| Net profit | ₹878 cr | ₹1,351 cr | −35.0% |
Sun Pharma
Q2 FY27, the quarter to 30 Sep 2026, against Q2 FY26
| Measure | Q2 FY27 | Q2 FY26 | Change |
|---|---|---|---|
| Revenue | ₹16,199 cr | ₹14,478 cr | +11.9% |
| Net profit | ₹1,989 cr | ₹3,118 cr | −36.2% |
Sources: Cipla S22, S18, S19, S15, S11, S6, S8 · Sun Pharma S9, S20, S17, S13
Who pays each company
Cipla
- Customers in India · 45.0% of revenueDistributors and retailers that sell Cipla's prescription brands, trade generics and consumer products to patients. Share is of FY26 revenue by customer location.
- Customers in the US · 24.4% of revenueBuyers of Cipla's generic medicines in the US: ₹6,872 crore of revenue in FY26, down from ₹7,899 crore in FY25.
- Customers in Africa · 15.2% of revenuePrivate-market buyers in South Africa and other African countries, and governments and global health programmes buying through tenders.
- Customers in the rest of the world · 15.4% of revenueBuyers in other emerging markets and Europe, and companies buying drug ingredients.
Sun Pharma
- Buyers in India · 33.8% of revenueMedicines sold in India, mostly under Sun Pharma's brands. Its sales team of over 16,000 people visits doctors. Share is of FY26 sales; drug-ingredient sales are counted in the region where they were sold.
- Buyers in the US · 30.3% of revenueGeneric and innovative medicines sold in the US. US formulation sales were US$1,904 million in FY26.
- Buyers in emerging markets · 20.1% of revenueMedicines sold in emerging markets. Formulation sales there were US$1,265 million in FY26, up 13%.
- Buyers in the rest of the world · 15.8% of revenueMedicines sold in other countries. Formulation sales there were US$969 million in FY26, up 14%.
Revenue by segment
Cipla
FY26
| Segment | Revenue | Share |
|---|---|---|
| One India | ₹12,680 cr | 45.0% |
| North America | ₹6,871 cr | 24.4% |
| One Africa | ₹4,287 cr | 15.2% |
| Emerging markets and Europe | ₹3,576 cr | 12.7% |
| API and others | ₹749 cr | 2.7% |
Sun Pharma
FY26
| Segment | Revenue | Share |
|---|---|---|
| India | ₹19,694 cr | 33.8% |
| United States | ₹17,620 cr | 30.3% |
| Emerging markets | ₹11,684 cr | 20.1% |
| Rest of the world | ₹9,222 cr | 15.8% |
Where the revenue comes from
Revenue by region, as each company splits it, with the period.
Cipla
FY26
- India45.0%
- United States24.4%
- Africa15.2%
- Rest of the world15.4%
Sun Pharma
Not on the Sun Pharma page.
Sources: Cipla S1
Borrowings and cash
Cipla
- Borrowings
- ₹267 cr
- Cash and investments
- ₹8,238 cr
On 30 Sep 2026.
On 30 Sep 2026 Cipla's cash and liquid investments were ₹7,971 crore more than its borrowings of ₹267 crore (Cityfort calculation from the Q2 FY27 results).
Sun Pharma
- Borrowings
- ₹2,694 cr
- Cash and investments
- ₹33,570 cr
On 30 Sep 2026.
On 30 Sep 2026 Sun Pharma's cash and liquid investments were ₹30,877 crore more than its borrowings, before it raised ₹7,816 crore through bonds in Oct 2026.
Sources: Cipla S6, S7, S8 · Sun Pharma S9, S1, S56, S40, S11, S44
Who owns each company
Cipla
- Promoters: 29.2%
- Foreign institutional investors (FIIs): 20.3%
- Indian institutions (DIIs): 34.9%
- Public: 15.6%
- Pledged: 0.0% of the promoter holding.
- Shareholding pattern at the end of Q2 FY27.
Sun Pharma
- Promoters: 52.7%
- Foreign institutional investors (FIIs): 14.4%
- Indian institutions (DIIs): 22.3%
- Public: 10.7%
- Pledged: 0.0% of the promoter holding.
- Shareholding pattern at the end of Q2 FY27.
Sources: Cipla S35, S36, S37, S38, S39, S40, S41, S42, S43, S44, S45, S46 · Sun Pharma S28, S29, S30, S31, S32, S33, S34, S35, S36, S37, S38, S39, S46, S47
What protects each business
What each page lists as protecting the business from competitors, each with its written reason. These describe business traits, not the share.
Cipla
- Respiratory medicines in India
CARE's Aug 2025 report put Cipla's share of India's respiratory medicine market at 25.3%, with Cipla second in urology and chronic medicines.
- US inhalers
Cipla's albuterol had 22% of the US albuterol inhaler market (IQVIA, week to 25 Sep 2026). Generic Ventolin launched in Q1 FY27 and generic Advair was approved on 27 Jul 2026.
- Size in India
₹14,839 crore of India medicine sales and a 5.8% share in the 12 months to Jun 2026 (AIOCD), against 8.5% for Sun Pharma.
- Africa
Cipla says it is second in South Africa's prescription market (IQVIA, Aug 2026). One Africa sold ₹4,287 crore in FY26, up 12%.
- Cash on hand
On 30 Sep 2026 cash and liquid investments of ₹8,238 crore against borrowings of ₹267 crore. CARE rated Cipla AAA (Stable) on 26 Aug 2025.
Sun Pharma
- Size in India
₹21,538 crore of India medicine sales and an 8.5% share in the 12 months to Jun 2026 (AIOCD), against 5.9% for the next name in the same list (Abbott, Abbott Healthcare and Novo combined).
- Reach to doctors
Over 16,000 field staff on 30 Jun 2026. Sun Pharma says it ranks first by prescriptions among 12 groups of doctors (SMSRC data).
- Brands
30 of India's top 300 medicine brands (AIOCD, Jun 2026). Its top 10 brands were about 17% of India revenue, so sales are spread across many brands.
- Product approvals
561 approved US generic applications and 58 approved new-drug applications on 30 Sep 2026, with 120 and 12 more pending.
- Cash on hand
On 30 Sep 2026 cash and liquid investments of ₹33,570 crore exceeded borrowings of ₹2,694 crore. CRISIL rated Sun Pharma AAA/Stable on 13 Oct 2026.
Sources: Cipla S47, S8, S87, S88, S14, S92, S16, S6, S7 · Sun Pharma S27, S10, S9, S40
Where growth could come from
Each page's growth drivers. The status compares progress with what the company itself said it would do; it is not a view on the share.
Cipla
- Medicines in India · Working: on track against what the company said₹3,516 crore, Q2 FY27 (+12%)
- North America · Behind: behind the company's own planUS$172 million, Q2 FY27 (US$233 million a year earlier)
- New US inhalers · Early: too early to judgeGeneric Ventolin launched Q1 FY27; generic Advair approved 27 Jul 2026
- Yurpeak (tirzepatide) in India · Early: too early to judgeLaunched 10 Dec 2025
- Africa · Mixed: partly on track₹1,171 crore, Q2 FY27 (−1%)
- Biosimilars and licensed medicines · New: recently announced60:40 biologics joint venture with Kemwell (Mar 2026)
Sun Pharma
- Branded medicines in India · Working: on track against what the company saidIndia sales +17.3%, Q2 FY27
- Innovative medicines · Working: on track against what the company saidUS$1,420 million, FY26 (+16.4% excluding a milestone payment)
- US generics · Mixed: partly on trackUS$455 million, Q2 FY27 (−8.2%)
- Organon purchase · Early: too early to judgeEnterprise value US$11.75 billion; not closed
- New plant in Madhya Pradesh · New: recently announced₹3,000 crore, approved 2 Dec 2025
Sources: Cipla S8, S85, S86, S19, S23, S21, S78, S87, S88, S14, S10, S16, S90, S9 · Sun Pharma S10, S18, S12, S11, S45, S50
Dividends, buybacks, auditor and credit rating
Dividends per share and buybacks for up to five years, the statutory auditor and the latest credit rating, as each page records them.
Cipla
- Dividends per shareFY22: ₹5.00 (16.0% of profit) · FY23: ₹8.50 (24.5% of profit) · FY24: ₹13.00 (25.5% of profit) · FY25: ₹16.00 (24.5% of profit) · FY26: ₹13.00 (27.1% of profit)
- BuybacksNone on the page in the last five years.
- AuditorB S R & Co. LLP, since 2026
- Credit ratingCARE Ratings: CARE AAA (long term), CARE A1+ (short term), bank facilities of ₹2,268 crore, outlook Stable (26 Aug 2025)
Sun Pharma
- Dividends per shareFY22: ₹10.00 (73.5% of profit) · FY23: ₹11.50 (32.6% of profit) · FY24: ₹13.50 (33.8% of profit) · FY25: ₹16.00 (35.1% of profit) · FY26: ₹16.00 (33.5% of profit)
- BuybacksNone on the page in the last five years.
- AuditorS R B C & Co LLP
- Credit ratingCRISIL: AAA (long term), A1+ (short term), outlook Stable (13 Oct 2026)
Sources: Cipla S5, S34, S4, S33, S3, S32, S2, S26, S1, S15, S83, S7, S47 · Sun Pharma S3, S7, S6, S5, S1, S40
Risks only one page tracks
Risks whose type the other company's page does not list. Both pages track risks of these types: regulation, legal cases. Every risk is on each company's page.
Cipla
- A few US products and partners (customer or supplier concentration)North America sales fell 13% in FY26 after generic Revlimid billing ended and supply of lanreotide, made by partner Pharmathen, was paused and later recalled. Achin Gupta said on 27 Oct 2026 that the US$1 billion run-rate aim does not include lanreotide.
- Price controls and competition (pricing)Cipla's FY26 annual report says "Government price controls, competitor and customer pressures collectively erode profitability", and names more competition in chronic medicines, particularly cardiometabolic (heart and blood-sugar) and anti-obesity medicines.
- Margins below earlier targets (execution)Cipla's FY26 EBITDA margin was 21.0%, against the 23.5–24.5% range management gave in May 2025. For FY27 management gave 18.5–20%; Cipla reported 18.7% in Q2 FY27.
- Delays in US launches (execution)Cipla said on 27 Jul 2026 it expected to launch generic Advair in Q2 FY27; on 27 Oct 2026 Achin Gupta said it "is getting launched in Q3". Cipla said on 14 Jan 2026 it expected lanreotide resupply in H1 FY27; it had not resumed by 27 Oct 2026.
Sun Pharma
- Organon purchase and new debt (debt)The Organon purchase has not closed. CRISIL says it will be funded with US$2.0–2.5 billion of cash and US$9.5–10.0 billion of debt. Sun Pharma's borrowings were ₹2,694 crore on 30 Sep 2026. Organon deal costs were ₹513 crore in H1 FY27, and Sun Pharma expects more.
- Falling US generic sales (competition)US formulation sales fell 8.2% in US dollars in Q2 FY27, to US$455 million; management said this was largely due to lower lenalidomide sales. CRISIL notes price pressure in US generics from authorised generics, buyer consolidation and other Indian makers.
- Small promoter pledge (governance)On 30 Sep 2026, 85,000 promoter-group shares held by Kumud Shantilal Shanghvi were pledged, 0.01% of the promoter holding. Pledged shares are given as loan collateral; a lender can sell them if a loan is not repaid.
Sources: Cipla S16, S21, S78, S80, S8, S10, S1, S28, S17, S88 · Sun Pharma S40, S9, S12, S10, S39, S38
Key facts
- How does Cipla make money compared with Sun Pharma?
- Cipla's revenue by segment in FY26: One India 45.0%, North America 24.4%, One Africa 15.2%, Emerging markets and Europe 12.7%, API and others 2.7%. Sun Pharma's revenue by segment in FY26: India 33.8%, United States 30.3%, Emerging markets 20.1%, Rest of the world 15.8%.
- Which is bigger by revenue, Cipla or Sun Pharma?
- Cipla reported revenue of ₹28,163 cr in FY26, and Sun Pharma reported revenue of ₹58,462 cr in FY26.
- How much net profit did Cipla and Sun Pharma report?
- Cipla reported a net profit of ₹3,879 cr in FY26, and Sun Pharma reported ₹11,479 cr in FY26.
- How much of every ₹100 did Cipla and Sun Pharma keep as profit?
- Cipla kept ₹13.4 of every ₹100 that came in during FY26, and Sun Pharma kept ₹19.0 in FY26 (Cityfort calculation from each company's annual report).
- How much do Cipla and Sun Pharma owe, and how much cash do they hold?
- Cipla had borrowings of ₹267 cr and cash and investments of ₹8,238 cr on 30 Sep 2026. Sun Pharma had borrowings of ₹2,694 cr and cash and investments of ₹33,570 cr on 30 Sep 2026.
- Who owns Cipla and Sun Pharma?
- Promoters held 29.2% of Cipla's shares at the end of Q2 FY27, with none of it pledged. Promoters held 52.7% of Sun Pharma's shares at the end of Q2 FY27, and 0.0% of the promoter holding was pledged. Both come from the shareholding patterns the companies filed with NSE and BSE.
- When do Cipla's and Sun Pharma's financial years end?
- Cipla and Sun Pharma both use the Indian financial year, April to March. The latest full year is FY26 on the Cipla page and FY26 on the Sun Pharma page.
Sources: Cipla S34, S5, S4, S33, S32, S3, S26, S2, S15, S1, S16, S31, S6, S7, S8 · Sun Pharma S7, S6, S5, S1, S27, S18, S9, S56, S40, S11, S44
Built from each company's page. Cipla updated 11 Nov 2026; Sun Pharma updated 11 Nov 2026.
Sources
Cipla
- S1Integrated Annual Report 2025-26 (FY26), Cipla Ltd (filed with NSE), 1 Jun 2026
- S2Integrated Annual Report 2024-25 (FY25), Cipla Ltd (filed with NSE), 19 Jun 2025
- S3Annual Report 2023-24 (FY24), Cipla Ltd (filed with NSE), 26 Jul 2024
- S4Annual Report 2022-23 (FY23; NSE zip), Cipla Ltd (filed with NSE), 18 Jul 2023
- S5Annual Report 2021-22 (FY22; NSE zip), Cipla Ltd (filed with NSE), 5 Sep 2022
- S6Q2 FY27 consolidated results, Integrated Filing (Financials) XBRL, Cipla Ltd (filed with NSE), 27 Oct 2026
- S7Unaudited financial results Q2 FY27 (quarter and half year ended 30 Sep 2026), Cipla Ltd (filed with NSE), 27 Oct 2026
- S8Press release: Q2 FY27 financial results, Cipla Ltd (filed with NSE), 27 Oct 2026
- S9Investor presentation Q2 FY27, Cipla Ltd (filed with NSE), 27 Oct 2026
- S10Q2 FY27 earnings call transcript (call 27 Oct 2026), Cipla Ltd (filed with NSE), 30 Oct 2026
- S11Q1 FY27 consolidated results, Integrated Filing (Financials) XBRL, Cipla Ltd (filed with NSE), 23 Jul 2026
- S14Q1 FY27 earnings call transcript (call 23 Jul 2026), Cipla Ltd (filed with NSE), 27 Jul 2026
- S15Q4 FY26 / FY26 consolidated results, Integrated Filing (Financials) XBRL, Cipla Ltd (filed with NSE), 13 May 2026
- S16Press release: Q4 FY26 and FY26 results, Cipla Ltd (filed with NSE), 13 May 2026
- S17Q4 FY26 earnings call transcript (call 13 May 2026), Cipla Ltd (filed with NSE), 15 May 2026
- S18Q3 FY26 consolidated results, Integrated Filing (Financials) XBRL, Cipla Ltd (filed with NSE), 23 Jan 2026
- S19Unaudited financial results Q3 FY26 (quarter ended 31 Dec 2025; scanned), Cipla Ltd (filed with NSE), 23 Jan 2026
- S21Q3 FY26 earnings call transcript (call 23 Jan 2026), Cipla Ltd (filed with NSE), 27 Jan 2026
- S22Q2 FY26 consolidated results, Integrated Filing (Financials) XBRL, Cipla Ltd (filed with NSE), 30 Oct 2025
- S23Press release: Q2 FY26 results, Cipla Ltd (filed with NSE), 30 Oct 2025
- S26Q4 FY25 / FY25 consolidated results, Integrated Filing (Financials) XBRL, Cipla Ltd (filed with NSE), 13 May 2025
- S28Q4 FY25 earnings call transcript (call 13 May 2025), Cipla Ltd (filed with NSE), 16 May 2025
- S31Press release: Q4 FY24 and FY24 results, Cipla Ltd (filed with NSE), 10 May 2024
- S32Q4 FY24 / FY24 consolidated results XBRL, Cipla Ltd (filed with NSE), 11 May 2024
- S33Q4 FY23 / FY23 consolidated results XBRL, Cipla Ltd (filed with NSE), 12 May 2023
- S34Q4 FY22 / FY22 consolidated results XBRL, Cipla Ltd (filed with NSE), 11 May 2022
- S35Shareholding pattern as of 31 Dec 2023 (NSE XBRL), NSE (company filing), 19 Jan 2024
- S36Shareholding pattern as of 31 Mar 2024 (NSE XBRL), NSE (company filing), 19 Apr 2024
- S37Shareholding pattern as of 30 Jun 2024 (NSE XBRL), NSE (company filing), 20 Jul 2024
- S38Shareholding pattern as of 30 Sep 2024 (NSE XBRL), NSE (company filing), 21 Oct 2024
- S39Shareholding pattern as of 31 Dec 2024 (NSE XBRL), NSE (company filing), 20 Jan 2025
- S40Shareholding pattern as of 31 Mar 2025 (NSE XBRL), NSE (company filing), 21 Apr 2025
- S41Shareholding pattern as of 30 Jun 2025 (re-filed 21 Oct 2025) (NSE XBRL), NSE (company filing), 21 Oct 2025
- S42Shareholding pattern as of 30 Sep 2025 (NSE XBRL), NSE (company filing), 21 Oct 2025
- S43Shareholding pattern as of 31 Dec 2025 (NSE XBRL), NSE (company filing), 21 Jan 2026
- S44Shareholding pattern as of 31 Mar 2026 (revised filing 11 Aug 2026; original 21 Apr 2026) (NSE XBRL), NSE (company filing), 11 Aug 2026
- S45Shareholding pattern as of 30 Jun 2026 (NSE XBRL), NSE (company filing), 21 Jul 2026
- S46Shareholding pattern as of 30 Sep 2026 (NSE XBRL), NSE (company filing), 21 Oct 2026
- S47CARE Ratings press release: Cipla Limited, bank facilities reaffirmed CARE AAA; Stable / CARE A1+, CARE Ratings Limited, 26 Aug 2025
- S78Update on lanreotide supply after USFDA observations at Pharmathen, Cipla Ltd (filing to NSE/BSE), 14 Jan 2026
- S80Cipla USA to recall unexpired lanreotide batches, Cipla Ltd (filing to NSE/BSE), 9 Mar 2026
- S8390th AGM approves B S R & Co. LLP; Walker Chandiok & Co LLP completes second term, Cipla Ltd (filing to NSE/BSE), 25 Jun 2026
- S85Launch of Yurpeak (tirzepatide) in India under distribution agreement with Eli Lilly, Cipla Ltd (filing to NSE/BSE), 10 Dec 2025
- S86Exclusive 5-year supply and marketing agreement for four Pfizer brands in India, Cipla Ltd (filing to NSE/BSE), 19 Dec 2025
- S87USFDA approval for first AB-rated generic of Ventolin HFA (albuterol), Cipla Ltd (filing to NSE/BSE), 23 Apr 2026
- S88USFDA approval for generic Advair Diskus, Cipla Ltd (filing to NSE/BSE), 27 Jul 2026
- S9060:40 biologics joint venture agreement with Kemwell Biopharma, Cipla Ltd (filing to NSE/BSE), 2 Mar 2026
- S92Sun Pharmaceutical Industries: investor presentation, September 2026 (India formulation market share chart, AIOCD AWACS MAT Jun 2026), Sun Pharmaceutical Industries Ltd (company IR site), 22 Sep 2026
Sun Pharma
- S1Annual Report FY26: Consolidated Financial Statements section, Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 6 Jul 2026
- S3Annual Report FY26: Board's Report and Corporate Governance section, Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 6 Jul 2026
- S5Annual Report FY25: Consolidated Financial Statements section, Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 4 Jul 2025
- S6Annual Report FY24: Consolidated Financial Statements section, Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 8 Jul 2024
- S7Annual Report FY23: Consolidated Financial Statements section, Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 27 Jul 2023
- S9Unaudited consolidated financial results Q2 FY27 (quarter and half year ended 30 Sep 2026), Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 30 Oct 2026
- S10Press release: Sun Pharma reports Q2FY27 results, Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 30 Oct 2026
- S11Q2 FY27 earnings presentation, Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 30 Oct 2026
- S12Q2 FY27 earnings call transcript (call 30 Oct 2026), Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 4 Nov 2026
- S13Unaudited consolidated financial results Q1 FY27 (quarter ended 30 Jun 2026), Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 31 Jul 2026
- S17Audited consolidated financial results Q4 FY26 and FY26, Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 22 May 2026
- S18Press release: Sun Pharma reports Q4FY26 and FY26 results, Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 22 May 2026
- S20Unaudited consolidated financial results Q3 FY26 (quarter ended 31 Dec 2025), Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 31 Jan 2026
- S27Investor presentation, September 2026 ("Creating Lasting Value"), Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 22 Sep 2026
- S28Shareholding pattern as of 31 Dec 2023 (NSE XBRL), NSE (company filing), 16 Jan 2024
- S29Shareholding pattern as of 31 Mar 2024 (NSE XBRL), NSE (company filing), 18 Apr 2024
- S30Shareholding pattern as of 30 Jun 2024 (NSE XBRL), NSE (company filing), 19 Jul 2024
- S31Shareholding pattern as of 30 Sep 2024 (NSE XBRL), NSE (company filing), 16 Oct 2024
- S32Shareholding pattern as of 31 Dec 2024 (NSE XBRL), NSE (company filing), 20 Jan 2025
- S33Shareholding pattern as of 31 Mar 2025 (NSE XBRL), NSE (company filing), 17 Apr 2025
- S34Shareholding pattern as of 30 Jun 2025 (NSE XBRL), NSE (company filing), 21 Jul 2025
- S35Shareholding pattern as of 30 Sep 2025 (NSE XBRL), NSE (company filing), 16 Oct 2025
- S36Shareholding pattern as of 31 Dec 2025 (NSE XBRL), NSE (company filing), 15 Jan 2026
- S37Shareholding pattern as of 31 Mar 2026 (NSE XBRL, revised filing), NSE (company filing), 17 Jun 2026
- S38Shareholding pattern as of 30 Jun 2026 (NSE XBRL), NSE (company filing), 17 Jul 2026
- S39Shareholding pattern as of 30 Sep 2026 (NSE XBRL), NSE (company filing), 15 Oct 2026
- S40Credit rating intimation with CRISIL rationale (13 Oct 2026, NCDs assigned AAA/Stable) and ICRA rationale, Sun Pharmaceutical Industries Ltd (filing to NSE/BSE), 13 Oct 2026
- S44Intimation: international credit ratings (Moody's Baa1, S&P BBB+), Sun Pharmaceutical Industries Ltd (filing to NSE/BSE), 8 Sep 2026
- S45Intimation and press release: definitive agreement to acquire Organon & Co., Sun Pharmaceutical Industries Ltd (filing to NSE/BSE), 27 Apr 2026
- S46Intimation: receipt of requests for reclassification from promoter group to public (Valia family), Sun Pharmaceutical Industries Ltd (filing to NSE/BSE), 14 May 2026
- S47Intimation: shareholders approve reclassification from promoter group to public, Sun Pharmaceutical Industries Ltd (filing to NSE/BSE), 26 Sep 2026
- S50Intimation: approval of ₹3,000 crore greenfield formulations facility in Madhya Pradesh, Sun Pharmaceutical Industries Ltd (filing to NSE/BSE), 2 Dec 2025
- S56Intimation: allotment of non-convertible debentures of ₹7,816 crore, Sun Pharmaceutical Industries Ltd (filing to NSE/BSE), 26 Oct 2026
Disclaimer
For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.
Investing in securities involves risk, including loss of capital. Before making any investment decision, do your own research and consider consulting a SEBI-registered investment adviser.
Cityfort, its owners and contributors may or may not hold securities of companies covered. Content is not an offer or solicitation to buy or sell any security.
Read the full disclaimerHide the full disclaimer
Cityfort publishes educational content that explains how listed companies work. Cityfort is not registered with the Securities and Exchange Board of India (SEBI) as an Investment Adviser or Research Analyst and does not provide investment advice, recommendations, ratings, price targets or any opinion on whether to buy, sell or hold any security.
All information is taken from publicly available sources, mainly company filings on BSE and NSE, which are listed on each page with dates. We work to keep it accurate and correct errors publicly, but we do not guarantee that it is complete, accurate or up to date. Any market price or price-based ratio shown is dated, may be out of date by the time you read it, and is included only to explain concepts.
Statements by company management are reported as statements, with their date and source; they are not our forecasts.